Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of isolated protein binding antigen psma and its application

A technology for binding proteins and chimeric antigen receptors, applied in the field of biomedicine, can solve the problems of unknown epitope information, lack of cross-germline cross-reactivity, etc., and achieve the effect of relieving and/or treating tumors

Active Publication Date: 2020-05-22
HARBOUR BIOMED (SHANGHAI) CO LTD
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Despite progress on PSMA targets, PSMA antibodies have many deficiencies that cannot be ignored, such as unknown epitope information for antibody binding, lack of data on cross-species cross-reactivity, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of isolated protein binding antigen psma and its application
  • A kind of isolated protein binding antigen psma and its application
  • A kind of isolated protein binding antigen psma and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0162] Example 1. Generation and screening of monoclonal hybridoma cells.

[0163] 1.1 Preparation of CHO-K1 / cyno PSMA cell stable transfection line.

[0164] Lentiviral particles packaged with nucleic acid sequences encoding human PSMA (GeneChem, cat#LVCON335) infected CHO-K1 at a ratio of M.O.I.=100 ((M.O.I. = (lentiviral particle titer*volume) / number of infected cells) Cells (ATCC, cat# CCL-61). Cells 48 hours post-infection were passaged at a ratio of 1:10 in F2K medium containing 8 µg / ml of selection resistance and 10% (w / v) fetal bovine serum1 About one week until the uninfected control group CHO-K1 was killed by screening resistance. Perform limiting dilution to 0.5 cells per well in a 96-well plate, continue to add medium containing screening resistance and culture for about 5 days to observe whether it is a monoclonal , Marked. Continue to culture in a 37-degree carbon dioxide incubator for about 1 week to 50% full, and expand the monoclonal to 6 wells. Use Tab antib...

Embodiment 2

[0171] Example 2. Sequencing, expression and purification of monoclonal PSMA antibodies.

[0172] The monoclonal PSMA antibody screened in Example 1 was sequenced, and the amino acid sequence is shown in Table 1.

[0173] Table 1. Sequencing results of monoclonal PSMA antibodies

[0174] sequence name SEQ ID NO: HCDR1 1 HCDR2 2 HCDR3 3 LCDR1 4 LCDR2 5 LCDR3 6 V H

15 V L

16

[0175] The heavy chain variable region sequence of the monoclonal PSMA antibody described above was subcloned into the pTT5 expression vector containing the signal peptide and human heavy chain IgG1 constant region (SEQ ID NO: 19). The light chain variable region sequence of the monoclonal PSMA antibody was subcloned into an expression vector containing the signal peptide and the human antibody light chain kappa constant region (SEQ ID NO: 20). After the recombinant plasmid was confirmed by sequencing, the plasmid was extracted with a la...

Embodiment 3

[0182] Example 3. Binding ability of monoclonal PSMA antibodies to cell surface PSMA.

[0183] HEK293 / hPSMA cells or CHO-K1 / cyno PSMA cells or LNCAP cells were cultured and expanded in T-75 flasks, and after reaching 90% confluency, the medium was aspirated and the cells were washed twice with PBS. The cells were trypsinized (Invitrogen, cat# 15050065) for about 1 minute, and the trypsin was neutralized with the medium. Cells were then washed twice with PBS, cell counts were determined, and cells were resuspended in PBS to 2 x 10 6 cells / ml. Add 100 µl of cell suspension to each well of a 96-well V-plate. Incubate with various concentrations of purified PSMA antibody or each isotype control antibody for 1 hour on ice. Cells were washed twice with PBS and incubated with goat anti-human (H+L)-Alexa Fluor 647 (Life technology, cat#A21445) for 30-45 min at 4°C. After washing with PBS again, the cells were analyzed for median fluorescence intensity (MFI) on a FACS Caton II flow...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The application provides a separate antigen conjugated protein. The separate antigen conjugated protein comprises HCDR1, HCDR2 and HCDR3 of VH with an amino acid sequence shown in SEQ ID NO: 15. The separate antigen conjugated protein comprises LCDR1, LCDR2 and LCDR3 of VL with an amino acid sequence shown in SEQ ID NO: 16. The application further provides a chimeric antigen receptor containing the separate antigen conjugated protein, an immunoconjugate, a nucleic acid encoding the separate antigen conjugated protein, a vector containing the separate antigen conjugated protein, a cell containing the nucleic acid or vector, a method for preparing the separate antigen conjugated protein and use of the separate antigen conjugated protein.

Description

technical field [0001] The present application relates to the field of biomedicine, in particular to an isolated protein that binds to the antigen PSMA and uses thereof. Background technique [0002] For men, prostate cancer is the most commonly diagnosed cancer and the third leading cause of death. According to statistics, in 2017, 160,000 patients were diagnosed with this tumor, and 26,000 deaths were caused (Siegel RL et al. , (2017) CA Cancer J Clin 67:7–30). Patients with localized cancer are often treated with surgery or radiation therapy (Walsh PC et al ., (2007) N Engl J Med 357:2696–705). However, 20-40% of patients who undergo radical prostatectomy, and 30-50% of those who undergo radiotherapy experience recurrence (Paller CJ et al. , (2013) Clin Adv Hematol Oncol 11:14–23). Standard therapy for metastatic cancer is usually androgen blockade, by means of bilateral orchiectomy or chemical castration (eg, administration of a luteinizing hormone recep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/30C07K19/00C12N15/13C12N15/62A61K47/55A61K47/68A61K39/00A61P35/00A61P13/08G01N33/68G01N33/574
CPCA61K39/0011A61K47/55A61K47/6869A61K2039/505A61P13/08A61P35/00C07K14/7051C07K16/3069C07K2317/73C07K2317/92C07K2319/33G01N33/57434G01N33/57484G01N33/6893
Inventor 黄冰何云戎一平
Owner HARBOUR BIOMED (SHANGHAI) CO LTD